Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study

• Main Authors: Caicun Zhou, Sang We Kim, Thanyanan Reungwetwattana, Jianying Zhou, Yiping Zhang, Jianxing He, Jin Ji Yang, Ying Cheng, Se Hoon Lee, Lilian Bu, Tingting Xu, Li Yang, Chao Wang, Ting Liu, Peter N. Morcos, You Lu, Li Zhang
• Other Authors: Sun Yat-Sen University Cancer Center
• Format: Article
• Published: 2020
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/51711
• Institution: Mahidol University

© 2019 Elsevier Ltd Background: Anaplastic lymphoma kinase-positive (ALK-positive)disease occurs in approximately 5% of all patients with non-small-cell lung cancer, with a similar incidence reported in Asian patients. This study is the first phase 3 randomised trial recruiting only Asian patients t...